Similar articles

• [Pharmacodynamic assessment of antibiotic sensitivity of Streptococcus pneumoniae].

  Soriano F. Soriano F. Med Clin (Barc). 1999 Jun 26;113(3):103-8. Med Clin (Barc). 1999. PMID: 10464745 Review. Spanish. No abstract available.
• Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.

  Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M. Fogarty CM, et al. J Antimicrob Chemother. 2003 Apr;51(4):947-55. doi: 10.1093/jac/dkg153. Epub 2003 Mar 13. J Antimicrob Chemother. 2003. PMID: 12654763 Clinical Trial.
• From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?

  Carter PL. Carter PL. Postgrad Med. 2002 Sep;112(3 Suppl):18-25. doi: 10.3810/pgm.09.2002.suppl19.101. Postgrad Med. 2002. PMID: 19667591
• In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.

  Okamoto H, Miyazaki S, Tateda K, Ishii Y, Yamaguchi K. Okamoto H, et al. Antimicrob Agents Chemother. 2001 Nov;45(11):3250-2. doi: 10.1128/AAC.45.11.3250-3252.2001. Antimicrob Agents Chemother. 2001. PMID: 11600393 Free PMC article.
• The clinical impact of macrolide resistance in pneumococcal respiratory infections.

  Garau J. Garau J. Int J Antimicrob Agents. 2001;18 Suppl 1:S33-8. doi: 10.1016/s0924-8579(01)00394-6. Int J Antimicrob Agents. 2001. PMID: 11574193 Review.